Pluristem Therapeutics, a developer of placenta-based cell therapies, has been granted a new patent by the Australian Patent Office. Patent #2007228341 covers the method and composition of matter for three-dimensional (3D) expansion of ...
Tags: 3D Cell Expansion, Pluristem
Cha Bio&Diostech, a South Korean partner of Pluristem Therapeutics, has filed its first investigational new drug (IND) application for Pluristem’s PLacental eXpanded (PLX) cells with the Korean Food and Drug Administration (KFDA). ...
Tags: PLX Cells, Cha Bio&Diostech
Pluristem Therapeutics, a developer of placenta-based cell therapies, is seeking FDA orphan drug status for its PLacental eXpanded (PLX) cells for the treatment of aplastic anemia. Pluristem earlier received an orphan drug status from the ...